Esketamine nasal spray for treatment‐resistant depression
Steve Chaplin
Prescriber May 1, 2020 DOI: 10.1002/psb.1845 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant major depression |
| Topics | Depression Esketamine |
| Citations | 1 |
| Key findings | Esketamine nasal spray (Spravato) is a new adjunctive therapy for treatment-resistant major depression, with its efficacy and adverse effects discussed based on clinical trial data. |
Abstract
A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. This article discusses the properties, clinical trial efficacy and adverse effects of this new treatment option.
Comparable studies
Other narrative reviews on esketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Long-term safety of ketamine and esketamine in treatment of depression | 2022 | Review | |
| Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms. | 2024 | Review | |
| Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review. Patients with depression | 2024 | Narrative review | |
| The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease | 2022 | Review |